PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (5R)-
Gastric Cancer
Eli Lilly and CompanySmall moleculePhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 65/ 100
Competitive context
283 Active assets in the Gastric Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Rivoceranib Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 4 | BBB |
FLUOROURACILUM I-Mab Biopharma US Limited | Phase 4 | BB |
Eloxatin Qilu Pharmaceutical Co., Ltd. | Phase 3 | BB |
Epirubicin Rondo Therapeutics | Phase 3 | BB |
Cyclophosphamide Vall d'Hebron Institute of Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
PROPANAMIDE, N-(4-(2,2-DIMETHYL-1-OXOPROPYL)-5-((((2-(ETHYLAMINO)ETHYL)SULFONYL)AMINO)METHYL)-4,5-DIHYDRO-5-PHENYL-1,3,4-THIADIAZOL-2-YL)-2,2-DIMETHYL-, (5R)- is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →